Keros Therapeutics KROS Stock
Keros Therapeutics Price Chart
Keros Therapeutics KROS Financial and Trading Overview
| Keros Therapeutics stock price | 11.61 USD |
| Previous Close | 11.43 USD |
| Open | 11.34 USD |
| Bid | 7.33 USD x 200 |
| Ask | 13.08 USD x 200 |
| Day's Range | 11.2 - 11.79 USD |
| 52 Week Range | 9.69 - 22.55 USD |
| Volume | 183.22K USD |
| Avg. Volume | 187.72K USD |
| Market Cap | 230.19M USD |
| Beta (5Y Monthly) | 1.124 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.22 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.83 USD |
KROS Valuation Measures
| Enterprise Value | -11688347 USD |
| Trailing P/E | N/A |
| Forward P/E | -1.7548367 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 15.331933 |
| Price/Book (mrq) | 0.877551 |
| Enterprise Value/Revenue | -0.778 |
| Enterprise Value/EBITDA | 0.121 |
Trading Information
Keros Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.124 |
| 52-Week Change | -22.80% |
| S&P500 52-Week Change | 12.38% |
| 52 Week High | 22.55 USD |
| 52 Week Low | 9.69 USD |
| 50-Day Moving Average | 11.26 USD |
| 200-Day Moving Average | 12.15 USD |
KROS Share Statistics
| Avg. Volume (3 month) | 187.72K USD |
| Avg. Daily Volume (10-Days) | 148.89K USD |
| Shares Outstanding | 19.83M |
| Float | 17.77M |
| Short Ratio | 5.91 |
| % Held by Insiders | 3.96% |
| % Held by Institutions | 95.09% |
| Shares Short | 1.14M |
| Short % of Float | 6.58% |
| Short % of Shares Outstanding | 5.72% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -655.84% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -11.78% |
| Return on Equity (ttm) | -17.16% |
Income Statement
| Revenue (ttm) | 15.01M USD |
| Revenue Per Share (ttm) | 0.56 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -58345000 USD |
| EBITDA | -96868000 USD |
| Net Income Avi to Common (ttm) | -83159000 USD |
| Diluted EPS (ttm) | -3.22 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 257.61M USD |
| Total Cash Per Share (mrq) | 12.99 USD |
| Total Debt (mrq) | 15.72M USD |
| Total Debt/Equity (mrq) | 5.99 USD |
| Current Ratio (mrq) | 21.96 |
| Book Value Per Share (mrq) | 13.23 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -47993000 USD |
| Levered Free Cash Flow (ttm) | -27174500 USD |
Profile of Keros Therapeutics
| Country | United States |
| State | MA |
| City | Lexington |
| Address | 1050 Waltham Street |
| ZIP | 02421 |
| Phone | 617 314 6297 |
| Website | https://www.kerostx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 92 |
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Q&A For Keros Therapeutics Stock
What is a current KROS stock price?
Keros Therapeutics KROS stock price today per share is 11.61 USD.
How to purchase Keros Therapeutics stock?
You can buy KROS shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Keros Therapeutics?
The stock symbol or ticker of Keros Therapeutics is KROS.
Which industry does the Keros Therapeutics company belong to?
The Keros Therapeutics industry is Biotechnology.
How many shares does Keros Therapeutics have in circulation?
The max supply of Keros Therapeutics shares is 19.83M.
What is Keros Therapeutics Price to Earnings Ratio (PE Ratio)?
Keros Therapeutics PE Ratio is now.
What was Keros Therapeutics earnings per share over the trailing 12 months (TTM)?
Keros Therapeutics EPS is -3.22 USD over the trailing 12 months.
Which sector does the Keros Therapeutics company belong to?
The Keros Therapeutics sector is Healthcare.
Keros Therapeutics KROS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
|
- | |||||
US Tech Composite
IXIC
US
|
26549.85 USD — |
+0.27
|
7.14B USD — | 26414.92 USD — | 26587.34 USD — | — - | 7.14B USD — |
|
US Tech Global Market Composite
NQGM
US
|
2049.7 USD — |
+1.04
|
— — | 2019.7 USD — | 2050.1 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
7256.33 USD — |
+1.48
|
— — | 7065.77 USD — | 7269.93 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1368.59 USD — |
+1.45
|
— — | 1337.51 USD — | 1371.51 USD — | — - | — — |
|
US Tech US 700 Small Cap Index
NQUS700SC
US
|
3062.46 USD — |
+0.43
|
— — | 3038.67 USD — | 3062.46 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
4000.62 USD — |
-1.26
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
